4D Molecular Therapeutics, Inc.
FDMT
$4.11
-$0.17-3.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.29% | -25.43% | -7.88% | -0.37% | -214.77% |
| Total Depreciation and Amortization | 4.76% | 4.86% | 1.88% | 5.35% | 8.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.97% | 13.57% | -27.96% | -3.98% | 18.84% |
| Change in Net Operating Assets | -143.93% | 1,330.09% | 80.45% | -630.12% | -78.57% |
| Cash from Operations | -56.04% | 2.82% | -3.97% | -18.00% | -2,005.04% |
| Capital Expenditure | 46.63% | -409.46% | 50.85% | -29.33% | -35.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -72.46% | 139.73% | 72.12% | -4,180.91% | -120.18% |
| Cash from Investing | -74.14% | 137.12% | 72.07% | -3,839.81% | -122.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.81% | -96.71% | -94.59% | 6,595.34% | -52.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.81% | -96.71% | -94.59% | 6,595.34% | -54.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,410.05% | 98.24% | -426.71% | 199.68% | -167.49% |
